ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,505.00
-0.71%
US Tech 100
19,000.00
-0.94%
Dow Jones
40,287.53
-0.93%
Brent Oil
81.875
0.00%
Bitcoin
66,601.35
-0.17%
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Zymeworks Inc (ZYME) Quote

Zymeworks Inc

Zymeworks Inc (ZYME)

NASDAQ
9.78
-0.03
(-0.31%)
Closed July 20 4:00PM
Delayed by 15 minutes
9.78
0.02
(0.20%)
After Hours: 4:11PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Key stats and details

Current Price
9.78
Bid
9.27
Ask
10.41
Volume
583,707
9.65 Day's Range 9.95
6.015 52 Week Range 13.14
Market Cap
693.615M
Previous Close
9.81
Open
9.91
Last Trade
2
@
9.68
Last Trade Time
Financial Volume
$ 5,710,341
VWAP
9.7829
Average Volume (3m)
637,900
Shares Outstanding
70,704,890
Dividend Yield
-
PE Ratio
-3.83
Earnings Per Share (EPS)
-1.68
Revenue
76.3M
Net Profit
-118.67M

About Zymeworks Inc

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiat... Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.zymeworks.com
Headquarters
North Vancouver, British Columbia, Can
Founded
1970
Zymeworks Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZYME. The last closing price for Zymeworks was $9.81. Over the last year, Zymeworks shares have traded in a share price range of $ 6.015 to $ 13.14.

Zymeworks currently has 70,704,890 shares outstanding. The market capitalization of Zymeworks is $693.61 million. Zymeworks has a price to earnings ratio (PE ratio) of -3.83.

ZYME Latest News

More News

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

VANCOUVER, British Columbia, July 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

July 11 2024
GlobeNewswire Inc.

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

VANCOUVER, British Columbia, June 17, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

June 17 2024
GlobeNewswire Inc.

Form 8-K - Current report

June 10 2024
Edgar (US Regulatory)

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

Pursuant to the terms of the licensing agreement between Zymeworks and BeiGene, Zymeworks is entitled to receive an $8 million milestone payment from BeiGene and remains eligible to receive up to...

June 10 2024
GlobeNewswire Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

May 28 2024
GlobeNewswire Inc.

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Completion of...

May 02 2024
GlobeNewswire Inc.

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

April 30 2024
GlobeNewswire Inc.

Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024

VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

April 11 2024
GlobeNewswire Inc.

Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting

VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

April 08 2024
GlobeNewswire Inc.

Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors

VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...

March 28 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.15-1.510574018139.9310.629.6568058410.16276484CS
41.2815.05882352948.510.628.215790669.23146213CS
121.6620.44334975378.1210.627.976379008.98815358CS
26-0.13-1.311806256319.9113.147.976080119.80680643CS
521.8923.95437262367.8913.146.0155254589.05962686CS
1563.453.29153605026.3813.146.0156223328.80746945CS
2603.453.29153605026.3813.146.0156223328.80746945CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
AUGXAugmedix Inc
$ 2.27
(147.71%)
24.14M
XCURExicure Inc
$ 0.5351
(76.02%)
14.02M
PSNLPersonalis Inc
$ 3.83
(56.33%)
22.8M
MDBHMDB Capital Holdings LLC
$ 10.675
(37.21%)
126.45k
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M
HYZNHyzon Motors Inc
$ 0.149
(-47.54%)
23.63M
MEDSTRxADE Health Inc
$ 14.92
(-33.45%)
223.27k
SILOSilo Pharma Inc
$ 2.50
(-27.95%)
11.93M
KITTNauticus Robotics Inc
$ 0.0935
(-27.46%)
28.43M
SERVServe Robotics Inc
$ 7.51
(185.55%)
266.26M
SXTP60 Degrees Pharmaceuticals Inc
$ 0.2602
(5.77%)
226.82M
NVDANVIDIA Corporation
$ 117.93
(-2.61%)
217.11M
SQQQProShares UltraPro Short QQQ
$ 8.46
(2.79%)
188.2M
SPWRSunPower Corporation
$ 0.6735
(-55.40%)
124.61M

Discussion

View Full Feed
ak-65 ak-65 4 minutes ago
Mean historical return and volatility for a 25 blue chips for long-term and short-term time intervals.

As all of you know, the historical expected return and volatility of stock is a very important characteristics of the stock stability and profitability. Here is the comparison of the
AAPL ABBV AXP
janice shell janice shell 5 minutes ago
Trump's comment about going after TSM semi-conductor stocks has lost nearly 5 trillion dollars in just a few days. Trump is great at one thing, LOSING money.

Isn't that a bit ungenerous? I'd say he's also very good at imagining he understands things about which he's entirely clueless.
TSM
BDEZ BDEZ 6 minutes ago
https://x.com/ninoboxer/status/1814338727671476406/photo/1
fuagf fuagf 7 minutes ago
Right, double standards if any. After learning more about Trump in 2016 it was almost beyond comprehension to me that any American could possibly vote for him. Now, even after absorbing the religion and the ideological factors, how any could vote for him is even more unimaginable. 14th vs last at
NYBob NYBob 9 minutes ago
Massive GOLD Revaluation Incoming, 'Sell at Your Own Peril': Andy Schectman - Commodity
Culture - VIDEO

[YT]unRNXsMTBhk[/YT]

https://youtu.be/unRNXsMTBhk

https://www.youtube.com/watch?v=unRNXsMTBhk

$Pelangio Exploration Inc. is a C
DANKRAN GOD GOLD
dailyinvestingadvice dailyinvestingadvice 10 minutes ago
https://youtu.be/AjeiWVXBxqI?si=8rMhmCwdbwWD-G8S
WNFT
janice shell janice shell 10 minutes ago
Are you by any chance related to conix?
BDEZ BDEZ 12 minutes ago
Biden’s Secret Service has denied a FOIA request

https://x.com/kylenabecker/status/1814385127369372020
Madgreekster Madgreekster 12 minutes ago
HONG KONG not china!!!
SWIN
Acme Investments Acme Investments 12 minutes ago
Tsnp is at the Top of the hill!! Sharp is still the King 👑 until dethroned!! Lol 😂
BCAP
fuagf fuagf 13 minutes ago
LOL i don't get it either, just saw dern, thought of darn and skated over it ..
4retire 4retire 14 minutes ago
I bought one share of stock from a DFMI shareholder to attend a DFMI shareholder gathering that Mike Fernandez was addressing in Anaheim, CA.about 13 years ago. You got me. I owned a total of one share that I paid $1 for. In that meeting Fernandez offered everyone there (except me) board member po
TMMI
Lakota-45 Lakota-45 15 minutes ago
A Notice to the Board; The WDLF / Decentral Life, Security Details
was updated today at OTC Markets, July 19, 2024 !!!
Note; ( No change on the OS ) !!!

~ A Reminder: The Company Profile was also recently Updated
at OTC Markets - in June of 2024 !!!

INQD WDLF
Lime Time Lime Time 16 minutes ago
This guy seems to have the knowledge to deal with FINRA and OTCM, so I'd suspect an even better performance than GS here. Just take the gains when they are there. OTC Market will pick up in 2025. 😀
BCAP
BDEZ BDEZ 17 minutes ago
From James Woods & David Paulides...

https://x.com/canammissing/status/1814517390094516316
fuagf fuagf 18 minutes ago
Why I Am Now Deeply Worried for America

"He didn't read Hitler's speeches for nothing. Leading by the nose..."

Feb. 12, 2024

https://static01.nyt.com/images/2024/02/14/multimedia/12krugman-wbcz/12krugman-wbcz-superJumbo.jpg?quality=75&auto=webp
Dam
CrashOverride CrashOverride 19 minutes ago
Buying next week that's what it means to me!
NWBO
nilremerlin nilremerlin 22 minutes ago
https://www.marijuanamoment.net/senators-will-vote-on-doobie-act-to-prevent-agencies-from-using-past-marijuana-use-to-deny-employment-and-security-clearances-next-week/
AYRWF
236T568 236T568 22 minutes ago
Pete nails it again

https://x.com/briantylercohen/status/1814520489819447778?s=19
Lime Time Lime Time 23 minutes ago
Maybe they can start pumping the eBikes. Like makes and models. These e-bike things cruise past my house faster than cars on a normal day.
SPQS
Acme Investments Acme Investments 23 minutes ago
In my opinion it will start to move as soon as he's granted the custo!! Just like it did when he bought in!! You're not the only one with expert access!!
BCAP
LOB LOB 25 minutes ago
Can you say where you saw or heard that or post it better yet? I can't find it anywhere. I know they killed the warrants because they expired then delisted them, but the stock all I could find was a possible July 1 meeting with no outcome shown yet. Saw July 8th mentioned in one doc mentioned that
AGRI

Your Recent History

NASDAQ
ZYME
Zymeworks
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved